AN2 Therapeutics, Inc.

NasdaqGS:ANTX Stock Report

Market Cap: US$38.8m

AN2 Therapeutics Past Earnings Performance

Past criteria checks 0/6

AN2 Therapeutics's earnings have been declining at an average annual rate of -22.1%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually.

Key information

-22.1%

Earnings growth rate

46.1%

EPS growth rate

Pharmaceuticals Industry Growth6.0%
Revenue growth raten/a
Return on equity-69.2%
Net Marginn/a
Last Earnings Update30 Sep 2024

Recent past performance updates

No updates

Recent updates

We're Keeping An Eye On AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Rate

Nov 21
We're Keeping An Eye On AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Rate

Is AN2 Therapeutics (NASDAQ:ANTX) In A Good Position To Invest In Growth?

Jul 04
Is AN2 Therapeutics (NASDAQ:ANTX) In A Good Position To Invest In Growth?

Here's Why We're Not Too Worried About AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Situation

Mar 23
Here's Why We're Not Too Worried About AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Situation

AN2 Therapeutics (NASDAQ:ANTX) Is In A Good Position To Deliver On Growth Plans

Dec 05
AN2 Therapeutics (NASDAQ:ANTX) Is In A Good Position To Deliver On Growth Plans

AN2 Therapeutics (NASDAQ:ANTX) Is In A Good Position To Deliver On Growth Plans

Aug 20
AN2 Therapeutics (NASDAQ:ANTX) Is In A Good Position To Deliver On Growth Plans

We Think AN2 Therapeutics (NASDAQ:ANTX) Can Afford To Drive Business Growth

May 09
We Think AN2 Therapeutics (NASDAQ:ANTX) Can Afford To Drive Business Growth

We're Not Very Worried About AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Rate

Feb 03
We're Not Very Worried About AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Rate

We're Hopeful That AN2 Therapeutics (NASDAQ:ANTX) Will Use Its Cash Wisely

Oct 21
We're Hopeful That AN2 Therapeutics (NASDAQ:ANTX) Will Use Its Cash Wisely

AN2 Therapeutics secures $17.8M contract from NIH

Sep 29

We Think AN2 Therapeutics (NASDAQ:ANTX) Can Afford To Drive Business Growth

Jul 01
We Think AN2 Therapeutics (NASDAQ:ANTX) Can Afford To Drive Business Growth

Revenue & Expenses Breakdown

How AN2 Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:ANTX Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 240-611550
30 Jun 240-651556
31 Mar 240-661458
31 Dec 230-651555
30 Sep 230-601549
30 Jun 230-541443
31 Mar 230-491536
31 Dec 220-431330
30 Sep 220-401127
30 Jun 220-38923
31 Mar 220-35621
31 Dec 210-28517
31 Dec 200-1516

Quality Earnings: ANTX is currently unprofitable.

Growing Profit Margin: ANTX is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: ANTX is unprofitable, and losses have increased over the past 5 years at a rate of 22.1% per year.

Accelerating Growth: Unable to compare ANTX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ANTX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (42%).


Return on Equity

High ROE: ANTX has a negative Return on Equity (-69.23%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 01:12
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

AN2 Therapeutics, Inc. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Liisa BaykoEvercore ISI
Douglas BuchananJMP Securities
Joseph SchwartzLeerink Partners LLC